GALT

Galectin Therapeutics Inc

Sep 17 • 04:00PM ET

4.59

+0.18 4.08 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRK GILD AMGN ABBV VRTX REGN BIIB NVAX EXEL

Index	-	P/E	-	EPS (ttm)	-0.64	Insider Own	31.41%	Shs Outstand	64.06M	Perf Week	-8.20%
Market Cap	294.04M	Forward P/E	-	EPS next Y	-0.44	Insider Trans	-0.08%	Shs Float	43.94M	Perf Month	17.69%
Enterprise Value	402.99M	PEG	-	EPS next Q	-0.11	Inst Own	16.35%	Short Float	18.18%	Perf Quarter	92.05%
Income	-40.46M	P/S	-	EPS this Y	35.53%	Inst Trans	7.65%	Short Ratio	11.44	Perf Half Y	190.51%
Sales	0.00M	P/B	-	EPS next Y	10.20%	ROA	-186.51%	Short Interest	7.99M	Perf YTD	255.81%
Book/sh	-1.86	P/C	21.35	EPS next 5Y	-	ROE	-	52W High	6.55 -29.92%	Perf Year	59.93%
Cash/sh	0.21	P/FCF	-	EPS past 3/5Y	-13.03% -23.89%	ROIC	-1229.32%	52W Low	0.73 532.20%	Perf 3Y	150.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	17.44% 9.40%	Perf 5Y	57.19%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	17.80%	Oper. Margin	-	ATR (14)	0.44	Perf 10Y	112.50%
Dividend Ex-Date	-	Quick Ratio	1.43	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.65	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.43	EPS Q/Q	40.19%	SMA20	1.82%	Beta	0.87	Target Price	6.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	21.80%	Rel Volume	0.30	Prev Close	4.41
Employees	15	LT Debt/Eq	-	Earnings	Aug 14 BMO	SMA200	118.94%	Avg Volume	698.57K	Price	4.59
IPO	Sep 04, 2002	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.00% -	Trades		Volume	206,311	Change	4.08%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Resumed	H.C. Wainwright	Buy	$6
Aug-13-20	Reiterated	H.C. Wainwright	Buy	$9 → $12
Feb-13-19	Initiated	B. Riley FBR	Buy	$11
Dec-07-17	Reiterated	H.C. Wainwright	Buy	$6 → $10
Nov-28-17	Reiterated	H.C. Wainwright	Buy	$3.50 → $6
Oct-19-17	Initiated	ROTH Capital	Buy
Mar-30-17	Upgrade	H.C. Wainwright	Neutral → Buy	$3.50
Oct-03-16	Downgrade	FBR & Co.	Outperform → Mkt Perform	$12 → $2
Sep-29-16	Downgrade	H.C. Wainwright	Buy → Neutral	$1.50
Sep-28-16	Downgrade	ROTH Capital	Buy → Sell
Mar-28-16	Resumed	H.C. Wainwright	Buy	$8
Sep-21-15	Initiated	H.C. Wainwright	Buy	$7
Aug-01-14	Downgrade	Aegis Capital	Buy → Hold
Jul-30-14	Reiterated	MLV & Co	Buy	$27 → $16
Jul-29-14	Reiterated	MLV & Co	Buy	$27 → $15
Apr-02-14	Reiterated	MLV & Co	Buy	$20 → $27
Feb-10-14	Reiterated	Aegis Capital	Buy	$16 → $32
Jan-09-14	Reiterated	Aegis Capital	Buy	$10 → $16
Dec-03-13	Initiated	MLV & Co	Buy	$20
Aug-19-13	Reiterated	Aegis Capital	Buy	$7 → $10

Show Previous Ratings

Sep-12-25 12:00PM	Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know (Zacks) -9.60%
Sep-02-25 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update (GlobeNewswire)
Jul-09-25 08:00AM	Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 (GlobeNewswire) +7.66%
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire) +37.66%
08:56AM	Loading…
Jun-10-25 08:56AM	Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension (GlobeNewswire)
May-15-25 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update (GlobeNewswire)
May-12-25 08:00AM	Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress (GlobeNewswire)
Apr-15-25 08:00AM	Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress (GlobeNewswire)
Apr-07-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-31-25 08:00AM	Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update (GlobeNewswire) -19.74%
Feb-18-25 08:00AM	Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial (GlobeNewswire) +8.51%
Jan-10-25 08:00AM	Galectin Therapeutics to Present at the 2025 MASH-TAG Conference (GlobeNewswire)
Dec-20-24 08:00AM	Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH (GlobeNewswire) -48.00%
Dec-09-24 09:35AM	Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks (Zacks) -6.85%
08:00AM	Loading…
Nov-18-24 08:00AM	Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting (GlobeNewswire)
Nov-14-24 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update (GlobeNewswire) -5.17%
Oct-15-24 08:00AM	Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting (GlobeNewswire)
Sep-30-24 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference (GlobeNewswire)
Sep-03-24 08:30AM	Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -7.24%
Aug-13-24 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update (GlobeNewswire) +6.64%
Aug-01-24 08:00AM	Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer (GlobeNewswire) -10.60%
Jun-04-24 08:00AM	Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress (GlobeNewswire)
May-15-24 12:53PM	GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +7.75%
08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference (GlobeNewswire)
Apr-09-24 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis (GlobeNewswire) +5.35%
Apr-05-24 08:52AM	GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023 (InvestorPlace) +24.33%
Mar-29-24 09:11AM	Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments (GuruFocus.com)
08:00AM	Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Mar-12-24 08:00AM	Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development (GlobeNewswire)
Nov-13-23 11:11AM	Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023 (GuruFocus.com) -7.14%
08:45AM	UPDATE Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update (GlobeNewswire)
08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update (GlobeNewswire)
Nov-03-23 08:00AM	Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2023, Hosted by the AASLD (GlobeNewswire)
Oct-23-23 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023 (GlobeNewswire)
Oct-12-23 08:00AM	Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors (GlobeNewswire)
Oct-03-23 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis (GlobeNewswire)
Sep-26-23 08:00AM	Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023 (GlobeNewswire)
Sep-13-23 05:22PM	Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 (GlobeNewswire) +6.70%
Sep-11-23 09:55AM	Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 (GlobeNewswire)
Sep-07-23 12:00PM	Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023 (GlobeNewswire) +7.32%
Aug-17-23 12:00PM	What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock (Zacks) +10.19%
Aug-14-23 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update (GlobeNewswire)
May-18-23 04:37PM	7 Short-Interest Stocks to Target for Explosive Gains (InvestorPlace) +6.38%
May-15-23 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update (GlobeNewswire)
Apr-27-23 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023 (GlobeNewswire)
Apr-18-23 08:00AM	Galectin Therapeutics Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases (GlobeNewswire)
Mar-30-23 08:00AM	Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.34%
Mar-16-23 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire)
Mar-02-23 08:00AM	Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) +8.29%
Jan-24-23 08:00AM	Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal (GlobeNewswire)
Jan-05-23 08:00AM	Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) -5.04%
Dec-13-22 09:55AM	Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now (Zacks)
Nov-29-22 08:00AM	Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders (GlobeNewswire)
Nov-28-22 08:00AM	Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit (GlobeNewswire)
Nov-14-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update (GlobeNewswire) +5.56%
Nov-01-22 08:00AM	Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2022, Hosted by the AASLD (GlobeNewswire)
Oct-14-22 08:00AM	Galectin Therapeutics to Present in Upcoming Conferences (GlobeNewswire) +5.19%
Oct-12-22 08:00AM	Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer (GlobeNewswire)
Oct-06-22 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire)
Sep-08-22 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022 (GlobeNewswire) +5.65%
Aug-15-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update (GlobeNewswire) +5.31%
Jul-26-22 08:00AM	Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 (GlobeNewswire)
Jun-21-22 08:00AM	Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress 2022 (GlobeNewswire)
May-23-22 08:00AM	Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress (GlobeNewswire)
May-16-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update (GlobeNewswire) -7.35%
May-11-22 11:20AM	Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y (Zacks) -6.47%
May-03-22 08:30AM	Nano Dimensions Preliminary Q1/2022 Revenues: Approximately $10.5 Million (GlobeNewswire)
Apr-15-22 07:20AM	Is Galectin Therapeutics Inc. (NASDAQ:GALT) Popular Amongst Insiders? (Simply Wall St.)
Apr-14-22 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) +10.13%
Mar-31-22 08:00AM	Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update (GlobeNewswire) -5.85%
Jan-06-22 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-21 08:00AM	Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein (GlobeNewswire)
Dec-13-21 08:00AM	Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting (GlobeNewswire)
Nov-15-21 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update (GlobeNewswire)
Nov-05-21 04:24PM	UPDATE Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting 2021, Hosted by the AASLD (GlobeNewswire)
Oct-27-21 08:00AM	Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting 2021, Hosted by the AASLD (GlobeNewswire)
Oct-05-21 03:39PM	UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021 (GlobeNewswire)
01:55PM	Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-21-21 08:00AM	Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein (GlobeNewswire)
Sep-09-21 09:00AM	Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Aug-30-21 08:00AM	Galectin Therapeutics Strengthens Leadership Team with Strategic Hires to Advance Programs in Cancer Immunotherapy and NASH Cirrhosis (GlobeNewswire)
Aug-16-21 09:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update (GlobeNewswire)
Jul-30-21 04:28AM	Here's What Galectin Therapeutics Inc.'s (NASDAQ:GALT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jul-09-21 09:25AM	Galectin Therapeutics Stock Surges After Robust Data From Belapectin/Keytruda Combo In Melanoma, Head & Neck Cancer (Benzinga) +25.00%
08:00AM	Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer (GlobeNewswire)
06:29AM	Galectin Therapeutics Soars on Positive Melanoma Treatment Data (TheStreet.com)
Jun-13-21 11:23PM	Is Galectin Therapeutics Inc. (GALT) A Good Stock To Buy? (Insider Monkey)
May-17-21 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update (GlobeNewswire)
Apr-27-21 09:28AM	Galectin Therapeutics to Present at 4th Global NASH Congress (GlobeNewswire)
Apr-19-21 08:00AM	World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Companys Galectin-3 Inhibitor, Belapectin (GlobeNewswire) +26.94%
Apr-15-21 09:00AM	Company News for Apr 15, 2021 (Zacks) -5.51%
Apr-14-21 08:28AM	Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response (Benzinga) +9.01%
Apr-13-21 07:01PM	Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy (GlobeNewswire)
Apr-06-21 08:00AM	Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study (GlobeNewswire) +35.27%
Mar-31-21 08:00AM	Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update (GlobeNewswire) +6.90%
Mar-08-21 08:00AM	OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy (GlobeNewswire)
Mar-04-21 08:00AM	Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference (GlobeNewswire) -6.44%

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CALLICUTT JACK W	Chief Financial Officer	Sep 12 '25	Option Exercise	1.37	8,706	11,927	16,320	Sep 15 12:45 PM
CALLICUTT JACK W	Chief Financial Officer	Sep 12 '25	Sale	6.44	8,706	56,054	7,614	Sep 15 12:45 PM
LEWIS JOEL	President and CEO	Sep 12 '25	Option Exercise	2.39	14,000	33,460	846,592	Sep 15 12:45 PM
LEWIS JOEL	President and CEO	Sep 12 '25	Sale	6.36	14,000	89,048	832,592	Sep 15 12:45 PM
LEWIS JOEL	Officer	Sep 12 '25	Proposed Sale	6.36	54,250	345,063		Sep 12 04:38 PM
CALLICUTT JACK W	Officer	Sep 12 '25	Proposed Sale	6.44	141,206	909,155		Sep 12 04:37 PM
ELDRED KARY	Director	Jul 21 '25	Buy	2.92	1,000	2,925	64,682	Jul 22 07:36 AM
FREEMAN KEVIN D	Director	Jul 17 '25	Buy	2.90	5,000	14,495	49,769	Jul 18 10:38 AM
CZIRR JAMES C	10% Owner	Jun 06 '25	Option Exercise	2.16	323,125	699,344	1,045,541	Jun 11 06:25 PM
Shlevin Harold H.	Director	Dec 30 '24	Buy	1.16	6,500	7,540	15,206	Dec 31 07:45 AM
Jamil Khurram	Chief Medical Officer	Dec 23 '24	Option Exercise	0.00	40,000	0	40,000	Dec 26 08:20 AM
Jamil Khurram	Chief Medical Officer	Dec 23 '24	Sale	0.88	13,654	12,044	26,346	Dec 26 08:20 AM
LEWIS JOEL	President and CEO	Dec 23 '24	Option Exercise	0.00	56,000	0	953,012	Dec 26 08:18 AM
LEWIS JOEL	President and CEO	Dec 23 '24	Sale	0.89	56,000	49,610	897,012	Dec 26 08:18 AM
CALLICUTT JACK W	Chief Financial Officer	Dec 23 '24	Option Exercise	0.00	40,000	0	47,614	Dec 26 08:18 AM
CALLICUTT JACK W	Chief Financial Officer	Dec 23 '24	Sale	0.89	40,000	35,492	7,614	Dec 26 08:18 AM
Zordani Richard A. Jr.	Director	Dec 24 '24	Buy	0.82	10,000	8,164	42,083	Dec 26 08:16 AM
ELDRED KARY	Director	Dec 24 '24	Buy	0.82	13,469	11,045	63,682	Dec 26 08:07 AM
FREEMAN KEVIN D	Director	Dec 24 '24	Buy	0.81	10,000	8,134	44,769	Dec 26 08:02 AM
Jamil Khurram	Officer	Dec 23 '24	Proposed Sale	1.04	13,654	14,200		Dec 23 04:19 PM
LEWIS JOEL	Officer	Dec 23 '24	Proposed Sale	1.04	56,000	58,240		Dec 23 04:18 PM
CALLICUTT JACK W	Officer	Dec 23 '24	Proposed Sale	1.04	40,000	41,600		Dec 23 04:17 PM
ELDRED KARY	Director	Oct 23 '24	Buy	2.60	500	1,300	50,213	Oct 23 01:39 PM
FREEMAN KEVIN D	Director	Oct 17 '24	Buy	2.64	1,300	3,432	34,769	Oct 17 04:03 PM
FREEMAN KEVIN D	Director	Oct 16 '24	Buy	2.70	5,000	13,500	80,000	Oct 16 04:12 PM
FREEMAN KEVIN D	Director	Oct 16 '24	Buy	2.70	5,000	13,500	33,469	Oct 16 04:12 PM
Boudes Pol F	Officer	Oct 04 '24	Proposed Sale	2.70	453,750	1,225,044		Oct 04 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GALT

Galectin Therapeutics Inc

Upgrade your FINVIZ experience